Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Burkitt Lymphoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Burkitt Lymphoma - Pipeline Review, H1 2015', provides an overview of the Burkitt Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Burkitt Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Burkitt Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Burkitt Lymphoma Overview 6 Therapeutics Development 7 Pipeline Products for Burkitt Lymphoma - Overview 7 Pipeline Products for Burkitt Lymphoma - Comparative Analysis 8 Burkitt Lymphoma - Therapeutics under Development by Companies 9 Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 10 Burkitt Lymphoma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Burkitt Lymphoma - Products under Development by Companies 13 Burkitt Lymphoma - Products under Investigation by Universities/Institutes 14 Burkitt Lymphoma - Companies Involved in Therapeutics Development 15 AstraZeneca PLC 15 Constellation Pharmaceuticals, Inc. 16 Karyopharm Therapeutics, Inc. 17 Millennium Pharmaceuticals, Inc. 18 Pharmacyclics, Inc. 19 Seattle Genetics, Inc. 20 Burkitt Lymphoma - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 alisertib - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AZD-6738 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 denintuzumab mafodotin - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ibrutinib - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Monoclonal Antibody Conjugated to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 selinexor - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 SH-7129 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SH-7133 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 SH-7139 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecules to Inhibit BET for Cancer - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Burkitt Lymphoma - Recent Pipeline Updates 55 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables
Number of Products under Development for Burkitt Lymphoma, H1 2015 7 Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Burkitt Lymphoma - Pipeline by AstraZeneca PLC, H1 2015 15 Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 16 Burkitt Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 17 Burkitt Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 18 Burkitt Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015 19 Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Burkitt Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 55
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.